Quest Diagnostics (DGX)
Provides clinical testing, pathology, and laboratory services through a North American network.
Something off on this page? Send us feedback.
Provides routine and advanced clinical laboratory testing, anatomic pathology, hospital reference testing, and hospital lab-management services, while ExamOne and Quanum serve insurers and healthcare organizations. Almost all revenue comes from Diagnostic Information Services, centered on a U.S. collection-and-testing network with an expanded Canadian presence through LifeLabs.
Provides routine, non-routine, and advanced clinical laboratory testing across oncology, genetics, brain health, and other specialties; anatomic pathology; hospital reference testing; and Collaborative Lab Solutions. Physicians, hospitals, and patients use a network of laboratories, patient service centers, couriers, mobile phlebotomists, and MyQuest access; ExamOne risk assessment and Quanum healthcare IT form the smaller Diagnostic Solutions group. Substantially all business is conducted in the United States, with LifeLabs extending the collection-and-testing network across parts of Canada.
Scale supports a broad test menu, specimen logistics, hospital partnerships, and data-enabled workflows. Almost all revenue comes from Diagnostic Information Services, primarily through fee-for-service testing billed to clients, patients, and third-party payers. Operations depend on physician referrals, health-plan access, reimbursement rules, accurate billing, healthcare regulation, data security, and consistent laboratory quality.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 21, 2026 | Truist Financial | Target | Target: $220 | Target: $260 |
| Sep 8, 2026 | UBS | Reiterate | Rating: —Target: $232 | Target: $245 |
| Jul 29, 2026 | Argus Research | Target | Target: — | Target: $260 |
| Jul 24, 2026 | UBS | Reiterate | Rating: —Target: $210 | Target: $232 |
| Jul 24, 2026 | Robert W. Baird | Target | Target: $236 | Target: $255 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $626.0M · Total debt $6.38B · Total assets $16.94B · Shareholders' equity $7.52B
- Revenue
- $3.04B
- Operating income
- $459.0M
- Net income
- $320.0M
HistoryDividendAnnual yieldUpcoming
| Institutions | 95.74% | 105.67M shares | |
|---|---|---|---|
| 1,126 holders · as of Jun 30, 2026 | |||
| Insiders | 0.44% | 483.4K shares | |
| 19 holders · as of Sep 3, 2026 | |||
| Other | 3.82% | 4.22M shares | |
| remainder | |||
110.37M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.40% | 9.28M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.55% | 7.23M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.55% | 6.13M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.00% | 5.52M | as of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 4.93% | 5.44M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 1, 2026 | J. E. Davis | director, officer: CEO and President | −10,000 | $242.72 |
| Aug 28, 2026 | Michael E. Prevoznik | officer: SVP & General Counsel | −22,677 | $243.11 |
| Jul 28, 2026 | Mark E. Delaney | officer: SVP & Chief Commercial Officer | −1,600 | $235.18 |
| Jun 4, 2026 | Karthik Kuppusamy | officer: SVP, Clinical Solutions | −8,147 | $200.00 |
| Jun 1, 2026 | J. E. Davis | director, officer: CEO and President | −10,000 | $194.14 |
- Labcorp
National lab network with broad specialty-testing overlap
- Natera
cfDNA diagnostics across women's health and oncology MRD
- Guardant Health
Liquid biopsy, MRD, and colorectal screening overlap
- NeoGenomics
Cancer-focused labs with pathology and NGS overlap
- Myriad Genetics
Hereditary cancer, prenatal, and pharmacogenomics tests
- OPKO Health
Regional BioReference labs plus urology diagnostics
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Quest Diagnostics | $232.84 | −4.92% | $27.03B | 26.0 | 20.3 | 2.3 | +10.2% |
| Labcorp | $309.13 | −3.69% | $26.32B | 26.6 | 16.3 | 1.8 | +5.8% |
| Natera | $385.65 | +4.05% | $53.08B | — | — | 19.6 | +37.7% |
| Guardant Health | $178.42 | +2.61% | $23.33B | — | — | 19.7 | +44.3% |
| NeoGenomics | $19.29 | −0.62% | $498.7M | — | 69.4 | 0.7 | +11.2% |
| Myriad Genetics | $3.96 | −1.32% | $378.7M | — | — | 0.5 | −10.5% |
| OPKO Health | $1.72 | +1.89% | $1.26B | — | — | 2.1 | +4.3% |
| Median | 26.6 | 42.8 | 2.0 | +8.5% |